CG Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the results of the 2026 Annual Meeting of Stockholders held by CG Oncology, Inc. on June 4, 2026. As of the record date of April 7, 2026, there were 88,009,980 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on four proposals with the following outcomes:
- Proposal 1 (Election of Directors): Christina Rossi and Victor Tong, Jr. were elected as Class II directors. Rossi received 67,531,501 votes for, while Tong received 62,401,874 votes for. Both faced significant broker non-votes (16,216,685 each).
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 83,711,522 votes for.
- Proposal 3 (Say-on-Pay): The advisory vote on executive compensation was approved with 65,894,959 votes for.
- Proposal 4 (Frequency of Say-on-Pay): Stockholders indicated a preference for annual advisory votes on executive compensation, with 66,962,791 votes for the 1-year option.
Guidance, Outlook, and Management Commentary
Based on the voting results for Proposal 4, the Company determined that future stockholder advisory votes on named executive officer compensation will be held every year until the next required advisory vote on frequency. The filing contains no financial guidance, risk factors, or management commentary regarding business operations.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 24, 2026, for detailed biographies of the elected directors and executive compensation specifics.
- Confirm the total number of shares outstanding and voting rights as of the record date (April 7, 2026).
- Review the Company's upcoming fiscal year 2026 financial reports for operational and liquidity metrics not included in this 8-K.